About: Kv7 Channels in Lung Diseases

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Kv7 Channels in Lung Diseases Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Kv7 Channels in Lung Diseases
Creator	Miceli, Francesco Cogolludo, Angel Gamper, Nikita Mondejar-Parreño, Gema Perez-Vizcaino, Francisco
source	Medline; PMC
abstract	Lung diseases constitute a global health concern causing disability. According to WHO in 2016, respiratory diseases accounted for 24% of world population mortality, the second cause of death after cardiovascular diseases. The Kv7 channels family is a group of voltage-dependent K(+) channels (Kv) encoded by KCNQ genes that are involved in various physiological functions in numerous cell types, especially, cardiac myocytes, smooth muscle cells, neurons, and epithelial cells. Kv7 channel α-subunits are regulated by KCNE1–5 ancillary β-subunits, which modulate several characteristics of Kv7 channels such as biophysical properties, cell-location, channel trafficking, and pharmacological sensitivity. Kv7 channels are mainly expressed in two large groups of lung tissues: pulmonary arteries (PAs) and bronchial tubes. In PA, Kv7 channels are expressed in pulmonary artery smooth muscle cells (PASMCs); while in the airway (trachea, bronchus, and bronchioles), Kv7 channels are expressed in airway smooth muscle cells (ASMCs), airway epithelial cells (AEPs), and vagal airway C-fibers (VACFs). The functional role of Kv7 channels may vary depending on the cell type. Several studies have demonstrated that the impairment of Kv7 channel has a strong impact on pulmonary physiology contributing to the pathophysiology of different respiratory diseases such as cystic fibrosis, asthma, chronic obstructive pulmonary disease, chronic coughing, lung cancer, and pulmonary hypertension. Kv7 channels are now recognized as playing relevant physiological roles in many tissues, which have encouraged the search for Kv7 channel modulators with potential therapeutic use in many diseases including those affecting the lung. Modulation of Kv7 channels has been proposed to provide beneficial effects in a number of lung conditions. Therefore, Kv7 channel openers/enhancers or drugs acting partly through these channels have been proposed as bronchodilators, expectorants, antitussives, chemotherapeutics and pulmonary vasodilators.
has issue date	2020-06-26(xsd:dateTime)
bibo:doi	10.3389/fphys.2020.00634
bibo:pmid	32676036
has license	cc-by
sha1sum (hex)	67bf917e3eaf13cf8644948b650c7f1eedc90363
schema:url	https://doi.org/10.3389/fphys.2020.00634
resource representing a document's title	Kv7 Channels in Lung Diseases
has PubMed Central identifier	PMC7333540
has PubMed identifier	32676036
schema:publication	Front Physiol
resource representing a document's body	covid:67bf917e3eaf13cf8644948b650c7f1eedc90363#body_text
is schema:about of	named entity 'KCNE2' named entity 'normal hearing' named entity 'intracellular' named entity '1.5' named entity 'cell types' named entity 'voltage' named entity 'transgenic mice' named entity 'Kv10.2' named entity 'retigabine' named entity 'Kv7.1' named entity 'hyperactivity' named entity 'O'Grady' named entity 'EGFR' named entity 'chromosomal' named entity 'Kv7' named entity 'KCNE3' named entity 'Kv7' named entity 'cardiac tissue' named entity 'Kv7' named entity 'KCNQ5' named entity 'pulmonary arterial hypertension' named entity 'Kv7' named entity 'Kv7.1' named entity 'Kv7' named entity 'desensitization' named entity 'CFTR' named entity 'hearing loss' named entity 'developmental disability' named entity 'bronchoconstriction' named entity 'Kv7.1' named entity 'Kv7' named entity '11q13' named entity 'KCNQ1' named entity 'flupirtine' named entity 'vasospasm' named entity 'distal' named entity 'mice' named entity 'dyspnea' named entity 'nebulized' named entity 'vasculature' named entity 'KCNQ5' named entity 'metastasis' named entity 'retigabine' named entity 'smooth muscle contraction' named entity 'C-fibers' named entity 'cystic fibrosis' named entity 'pulmonary artery' named entity 'β2-adrenergic receptor agonists' named entity 'myocytes' named entity 'voltage-gated channel' named entity 'Kv7.4' named entity '5-HT transporter' named entity 'pulmonary hypertension' named entity 'flupirtine' named entity 'hypersensitivity' named entity 'rat' named entity 'EGFR' named entity 'S53' named entity 'mice' named entity 'expression levels' named entity 'airway epithelia' named entity 'kinetics' named entity 'Kv7.2' named entity 'Kv7.1' named entity 'Kv7' named entity 'viral proteins' named entity 'respiratory diseases' named entity 'Kv7.1' named entity 'therapeutic target' named entity 'epithelial cells' named entity 'mRNA' named entity 'heteromeric' named entity 'Kv7' named entity 'bronchoconstrictor' named entity 'COS cells' named entity 'gefitinib' named entity 'KCNQ4'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software